# TABLE OF CONTENTS

1. General introduction

2. Towards personalized treatment: predictors of short term HAQ response in recent onset active RA are different from predictors of rapid radiological progression

3. Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial

4. A multi-biomarker based disease activity (MBDA) score system compared to a conventional disease activity score (DAS) system in the BeSt rheumatoid arthritis (RA) study

5. The association of treatment response and joint damage with ACPA-status in recent onset RA: a subanalysis of the 8-year follow-up of the BeSt study

6. Large joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints

7. Early local swelling and tenderness are independent predictors of large joint damage after 8 years of DAS steered treatment in recent onset RA patients

8. Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis

9. Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated according to a dynamic strategy - A subanalysis from the BeSt study

10. Risk factors for reported influenza and flu-like symptoms in patients with rheumatoid arthritis

11. Summary and conclusion
Benefits and risks of targeted treatment in rheumatoid arthritis

The research presented in this thesis was performed at the Rheumatology Department of Leiden University Medical Center, Leiden, The Netherlands and was financially supported by the Dutch College of Health Insurances, Schering-Plough B.V. and Janssen Biologics B.V.

ISBN: 978-90-9026931-3
Copyright © L. Dirven, 2012

No part of this thesis may be reproduced in any form without written permission from the author or, when appropriate, of the publishers of the publications.

Graphic design: RON Graphic Power
Printing: Drukkerij Koopmans, Zwanenburg

The printing of this thesis was financially supported by ABBOTT B.V., Merck Sharpe & Dohme B.V., MV Ingenieursbureau B.V., Novartis Pharma B.V., Pfizer B.V., the Dutch Arthritis Association (het Reumafonds), Roche Nederland B.V., Sandoz B.V. and UCB Pharma B.V.